CRANE COMPANY
In the published model solve dated 2026-Q2, anchored at $207.00, CRANE COMPANY (CR) is priced for today's economics sustained for ~6.8 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed July 25, 2026 from SEC EDGAR filings.
• Valves and related process products are the largest single revenue line at 41%, with the aerospace and defense lines together supplying most of the rest, so this is an industrial parts maker with a flight-hours business attached rather than the reverse. • The price is the risk: at roughly 33 times company-wide operating income it embeds today's economics persisting for about 8.5 years, a run only about 18% of comparable fast growers have managed. • Growth is being purchased as well as earned,
Is CR overvalued? See what's priced in →
543 institutional managers reported holding CR in 13F filings for the quarter ended 2026-03-31. Together they hold about 73% of the company; the top 10 hold 35%. 78 opened new positions that quarter. Held by BlackRock, Vanguard Group, Capital Group (American Funds), among others. On the short side, 1.6M shares were sold short as of the 2026-06-15 count, about 3% of shares outstanding (2.9 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
It pays a dividend, and has paid one every year in our records (5 and counting); the current rate is $0.92 a share annually. Cash returned over the past three years: $242.10M in dividends.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at CR over the trailing three years: 2026: 5 buys totaling $987k. 12 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
CR's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-11-02 | +11.8% | +16.0% |
| 2024-02-27 | +8.8% | +13.7% |
| 2024-05-02 | +1.4% | +2.8% |
| 2024-08-01 | -4.6% | +0.9% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
CR's latest 8-K filings: 2026-07-28 (items 2.02, 9.01); 2026-04-27 (items 5.02, 9.01); 2026-04-27 (items 5.07); 2026-04-27 (items 2.02, 9.01); 2026-01-29 (items 5.02).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 25, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.